GAITHERSBURG, Md. and
SHANGHAI, June 30, 2020 /PRNewswire/ -- Cellular
Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a
biopharmaceutical firm engaged in the drug development of
immunotherapies for cancer and stem cell therapies for degenerative
diseases, announced it will host a virtual R&D Showcase at
8:00 AM Eastern Standard Time on
Monday, July 13, 2020.
The event will feature an overview and update of clinical and
pre-clinical programs currently being researched and developed by
CBMG.
Speakers include:
Tony (Bizuo) Liu – CEO and CFO
Yihong Yao, PhD – CSO
Michael Humphries, MD – Head of
Development Strategy
The live webcast will include video and slide presentations and
can be accessed from the investors section of the CBMG website at
www.cellbiomedgroup.com.
To RSVP for the event, please e-mail Sarah Kelly, Director of Communications at
sarah.kelly@cellbiomedgroup.com
About Cellular Biomedicine Group, Inc.
Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) develops
proprietary cell therapies for the treatment of cancer and
degenerative diseases. The company conducts immuno-oncology and
stem cell clinical trials in China
using products from its integrated GMP laboratory. The Company's
GMP facilities in China,
consisting of twelve independent cell production lines, are
designed and managed according to both China and U.S. GMP standards. Its Shanghai facility includes a "Joint Laboratory
of Cell Therapy" with GE Healthcare and a "Joint Cell Therapy
Technology Innovation and Application Center" with Thermo Fisher
Scientific. These partnerships focus on improving manufacturing
processes for cell therapies. CBMG currently has ongoing CAR-T
Phase I clinical trials in China.
The China NMPA (formerly CFDA) approved the Company's IND
application for a Phase II trial for AlloJoin®, CBMG's
"Off-the-Shelf" allogenic haMPC therapy for the treatment of Knee
Osteoarthritis (KOA), and has accepted the Company's IND
application for a Phase II trial for ReJoin® autologous haMPC
therapy for the treatment of KOA. The NMPA has also accepted CBMG's
dossier for an IND application for clinical trials of anti-BCMA
CAR-T. CBMG is included in the broad-market Russell 3000® Index the
small-cap Russell 2000® Index and the Loncar China BioPharma index.
To learn more about CBMG, please
visit www.cellbiomedgroup.com.
Forward-Looking Statements
Statements in this press release relating to plans, strategies,
trends, specific activities, and other statements that are not
descriptions of historical facts, including our plans to host a
virtual R&D Showcase or expectations regarding our clinical and
pre-clinical programs, may be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking information is inherently subject to risks and
uncertainties, and actual results could differ materially from
those currently anticipated due to a number of factors, which
include any risks detailed from time to time in CBMG's reports
filed with the Securities and Exchange Commission, Annual Reports
on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports
on Form 8-K, including risks relating to the impact of the COVID-19
pandemic on our operations, including risks associated with the
evolving COVID-19 pandemic and actions taken in response to it.
Generally, the words "believes," "anticipates," "may," "will,"
"should," "could," "expect," "plans," "intend," "estimate,"
"projects," "presents," "potential," "continue" and similar
expressions or the negative thereof or comparable terminology are
intended to identify forward-looking statements. These statements
reflect our current views with respect to future events or to
our future activities and involve known and unknown risks,
uncertainties and other factors which may cause our actual
activities, actions or achievements to be materially different from
any future activities, actions or achievements expressed or implied
by the forward-looking statements. Given these uncertainties, you
should not place undue reliance on these forward-looking
statements.
Company/Investor Contact:
Derrick C. Li
Head of Strategy and Investor Relations, CBMG
Phone: 917-717-0994
Email: derrick.li@cellbiomedgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cellular-biomedicine-group-cbmg-to-host-investor-rd-showcase-highlighting-updates-to-clinical-programs-301086252.html
SOURCE Cellular Biomedicine Group, Inc.